# Dapagliflozin in STEMI

> **NCT06174753** · PHASE3 · RECRUITING · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 256 (estimated)

## Conditions studied

- ST Elevation Myocardial Infarction
- Myocardial Infarction

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DIAGNOSTIC_TEST:** CMR

## Key facts

- **NCT ID:** NCT06174753
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06174753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06174753, "Dapagliflozin in STEMI". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06174753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*